NASDAQ: CUVLClinuvel Pharmaceuticals Ltd Stock
$5.07-0.08 (-1.55%)
Updated Oct 30, 2026
CUVL Price
$5.07
Fair Value Price
N/A
Market Cap
$255.67M
52 Week Low
$4.88
52 Week High
$8.20
P/E
11.02x
P/B
1.36x
P/S
N/A
PEG
0.33x
Dividend Yield
0.57%
Revenue
$64.32M
Earnings
$23.18M
Gross Margin
82.9%
Operating Margin
50.87%
Profit Margin
36%
Debt to Equity
0.08
Operating Cash Flow
$13M
Beta
-0.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CUVL Overview
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CUVL's potential to beat the market
- CUVL doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CUVL
RankedUnranked of 454
RankedUnranked of 454
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $927.89 | A | |
| $10.44 | A | |
| $370.33 | A |
Be the first to know about important CUVL news, forecast changes, insider trades & much more!
CUVL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CUVL scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CUVL ($5.07) is trading below its intrinsic value of $6.76, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CUVL is good value based on its earnings relative to its share price (11.02x), compared to the US market average (46.08x)
P/E vs Market Valuation
CUVL is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CUVL due diligence checks available for Premium users.
Valuation
CUVL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
11.02x
Industry
16.38x
Market
46.08x
CUVL is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CUVL is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CUVL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.36x
Industry
5.17x
CUVL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CUVL price to earnings growth (PEG)
For valuing profitable companies with growth potential
CUVL is good value based... subscribe to Premium to read more.
PEG Value Valuation
CUVL's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
CUVL's Earnings (EBIT) of $32.72M... subscribe to Premium to read more.
Interest Coverage Financials
CUVL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$204.0M
Liabilities
$15.4M
Debt to equity
0.08
CUVL's short-term assets ($196.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CUVL's short-term assets ($196.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CUVL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
CUVL's operating cash flow ($12.91M)... subscribe to Premium to read more.
Debt Coverage Financials
CUVL vs Biotech Stocks
Clinuvel Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.